“Efficacy and Safety of Risankizumab Compared With Apremilast in Patients With Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s257. https://doi.org/10.25251/skin.7.supp.257.